Gemcitabine hydrochloride , 98% , 122111-03-9

Synonym(s):
2′-Deoxy-2′,2′-difluorocytidine; dFdC;dFdC;dFdCyd;Gemzar (Lilly)

CAS NO.：122111-03-9

Empirical Formula: C9H12ClF2N3O4

Molecular Weight: 299.66

MDL number: MFCD01735988

EINECS: 601-823-3

PRODUCT Properties

• Melting point: >250°C dec.
• alpha: D +48°; 365 +257.9° (c = 1.0 in deuterated water)
• storage temp.: 2-8°C
• solubility: H2O: ≥10mg/mL
• form: White powder
• color: White
• λmax: 268nm(H2O)(lit.)
• Merck: 14,4386
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month.

Description and Uses

Gemcitabine is a novel nucleoside analog that was launched in 1995 in the Netherlands for the treatment of non-small cell lung cancer (nsclc) and in Sweden for pancreatic cancer. Gemcitabine is a prodrug which is phosphorylated intracellularly by deoxycytadine kinase to its active forms, the di- and triphosphates which bind to DNA competitively. This insertion inhibits processes required for DNA synthesis and metabolism, the essential function for both cell replication and repair. Furthermore, gemcitabine displays an extraordinary array of self-potentiating mechanisms that increase the concentration and prolong the retention of its active nucleotides in tumor cells. The title compound has shown activity against a wide spectrum of human solid tumors including colon, mammary, breast, bladder cancers. Synergistic activity of gemcitabine with other anticancer agents such as cisplatin has been reported.

An antineoplastic.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H360
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501
• Hazard Codes: Xn,Xi
• Risk Statements: 21-36/38-46-62-63
• Safety Statements: 25-26-36/37-53
• WGK Germany: 3
• RTECS: HA3840000
• HS Code: 29420000